← Oncology Approval Tracker

FDA DECISION ·

Rubraca

rucaparib · Clovis Oncology

Accelerated approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Dec 17, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Patients with metastatic castration-resistant prostate cancer associated with a deleterious germline or somatic BRCA mutation after androgen receptor-directed therapy and taxane chemotherapy.

LAMPGEN ANALYSIS

Why it matters

Made a PARP inhibitor available in a post-taxane BRCA-defined prostate cancer population under accelerated approval.

What research teams should watch

Capture the source of the BRCA result and both prior therapy classes when confirming eligibility.

PRIMARY RECORDS

Sources